In Vivo Optical Molecular Imaging of Matrix Metalloproteinase Activity following Celecoxib Therapy for Colorectal Cancer
Authors:
Open Access
- 1 September 2012
- journal article
- Published by SAGE Publications in Molecular Imaging
- Vol. 11 (5) , 417-25
Abstract
We present an optical molecular imaging approach to measure the efficacy of the cyclooxygenase-2 (COX-2) inhibitor celecoxib on tumor growth rate through its effect on matrix metalloproteinase (MMP) activity. A xenograft model of colorectal cancer was generated in nude mice, which were then randomized to receive celecoxib versus vehicle. MMP activity was measured by an enzyme-activatable optical molecular probe. A novel genetically engineered mouse (GEM) model of colorectal cancer was also used to assess celecoxib's effect on MMP activity, which was measured by quantitative fluorescence colonoscopy. Subcutaneously implanted xenograft tumors were 84% (SD 20.2%) smaller in volume in the treatment group versus the control group. Moreover, treated animals exhibited only a 7.6% (SEM 9%) increase in MMP activity versus 106% (SEM 8%) for untreated animals. There was an apparent linear relationship ( r = .91) between measured MMP activity and tumor growth rate. Finally, in the GEM model experiment, treated murine tumors remained relatively unchanged in volume and MMP activity; however, untreated tumors grew significantly and showed an increase in MMP activity. This method may provide for the improved identification of patients for whom COX-2 inhibition therapy is indicated by allowing one to balance the patient's cardiovascular risk with the cancer's responsiveness to celecoxib.Keywords
This publication has 42 references indexed in Scilit:
- Matrix metalloproteinases in colorectal cancer: Is it worth talking about?Cancer and Metastasis Reviews, 2004
- Cyclo-oxygenase 2 inhibition in colorectal cancer therapyBritish Journal of Surgery, 2003
- Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase geneProceedings of the National Academy of Sciences, 2003
- Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.2003
- Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.2002
- How Matrix Metalloproteinases Regulate Cell BehaviorAnnual Review of Cell and Developmental Biology, 2001
- Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2Nature Reviews Cancer, 2001
- Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitorOncogene, 2001
- Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growthGastroenterology, 2001
- Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models.2000